FDA clears Teleflex's ArrowEvolution catheter
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Teleflex's ArrowEvolution peripherally inserted central catheter. The device incorporates an antimicrobial coating, Chlorag+ard, a chlorhexedine-based solution that has been chemically bonded to the surface of the catheter. This should help protect against central line-associated bloodstream infections and therefore reduce the incidence of hospital-acquired infections, Teleflex believes. The catheter is inserted into a peripheral vein and then advanced through increasingly larger veins, towards the heart, and can be used to deliver chemotherapy or antibiotics. The Limerick, Pennsylvania firm plans to launch the product in the US in the fourth quarter.